What an SPC is, and what it says about these medicines
The Summary of Product Characteristics, or SPC, is the legally approved document describing what a medicine is licensed for, how it is dosed, who must not take it and what side effects occur at what frequency. It is written by the manufacturer and approved by the regulator, which in Ireland means the European Medicines Agency and the HPRA. It is free to read, it is the document your prescriber works from, and it is the source quoted for every clinical statement on this site. If a claim about one of these medicines is not in the SPC or a published trial, treat it as marketing.
What an SPC actually is
Every licensed medicine in the European Union has one. It is the reference document that defines the terms of the licence, and it is what a prescriber, a pharmacist and a regulator all work from. It is not promotional material: the manufacturer writes it, but the regulator approves every word, and changing it requires a formal variation.
Two consequences follow. Anything stated in the SPC is a claim the manufacturer has had to substantiate. And anything not in it — a use, a dose, an outcome — sits outside the licence, however widely it is repeated.
What it tells you that nothing else will
- The licensed indication. The one that decides your bill in Ireland. Ozempic is licensed for type 2 diabetes, not weight loss. Wegovy is licensed for weight management. Same molecule, different licence, and different State cover.
- The dosing and titration schedule. The exact step-up, in weeks. This is usually where the answer to “why has nothing happened yet” lives.
- Contraindications. Who must not take it. Previous pancreatitis, and a personal or family history of medullary thyroid carcinoma or MEN 2, both appear here.
- Interactions. The oral contraceptive warning for tirzepatide is in the Mounjaro SPC, and most people have never heard of it because nobody reads it.
- Side effects with frequencies. Not “may cause nausea” but how commonly, graded from very common to very rare.
- Pregnancy and breastfeeding. The washout periods before a planned pregnancy come from here.
Where to find each one
All of them are free, and there are two reliable sources.
- The European Medicines Agency at ema.europa.eu, which holds the EU-wide product information for centrally authorised medicines. All five of these are there.
- The HPRA at hpra.ie, which holds the Irish product information.
Search the brand name and look for the document headed “Summary of Product Characteristics”, or the product information PDF in the EMA listing. Our product pages cover the same ground in plain language: Ozempic, Mounjaro, Wegovy, Saxenda and Rybelsus.
The SPC and the leaflet in the box
They are the same facts written for different readers. The Patient Information Leaflet that comes in the box is the plain-language version, approved alongside the SPC. The SPC is written for prescribers and carries more detail, including the frequency tables and the pharmacology.
If you want the short version, read the leaflet. If you want to check a specific claim someone has made online, read the SPC.
How to read it without a clinical background
It is dense but navigable, and four sections carry most of what a patient wants.
- Section 4.1, Therapeutic indications. What it is licensed for. Two lines, and the most consequential two lines in the document.
- Section 4.2, Posology. The dosing schedule and titration steps.
- Section 4.3, Contraindications. Who must not take it.
- Section 4.8, Undesirable effects. Side effects with frequencies attached.
Section 5.1 holds the clinical trial data if you want the actual numbers rather than somebody’s summary of them.
Why we quote it rather than paraphrasing
Weight loss medicine attracts a great many confident claims. The SPC settles most of them, and it costs nothing to check.
Our methodology page sets out the rule: clinical statements come from the SPC or a published trial, and the source is named on the page. Where the SPC is silent we say so rather than filling the gap. Where evidence is contested, such as microdosing, we say that too.
If you ever find a clinical statement on this site that the SPC contradicts, tell us and we will correct it. That is the entire point of naming the source.
Ozempic spc: common questions
The Summary of Product Characteristics for Ozempic is the regulator-approved document setting out what it is licensed for, how it is dosed, who must not take it and what side effects occur at what frequency. It is published free by the European Medicines Agency and the HPRA.
On the European Medicines Agency website at ema.europa.eu, or the HPRA at hpra.ie. Search the brand name and look for the document headed Summary of Product Characteristics, or the product information PDF in the EMA listing.
They contain the same approved facts for different readers. The Patient Information Leaflet is the plain-language version. The SPC is written for prescribers and carries more detail, including side effect frequency tables and the clinical trial data.
Section 4.1, Therapeutic indications. For these medicines it is the most consequential part of the document, because the licensed indication decides whether State schemes apply to your prescription in Ireland.
It reports the trial results in section 5.1, as averages across the trial population. It does not predict an individual outcome, and the spread underneath those averages is wide in both directions.
Yes. Both the European Medicines Agency and the HPRA publish it at no charge, and no registration is needed.